March 22nd 2023
Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Trekking Through the Latest Updates for ROS1-Targeted Therapies
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC
Navigating the Latest Data on NTRK-Targeted Therapies
Community Practice Connections™: 17th Annual New York Lung Cancers Symposium
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer
Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC
Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC
Onco-Nurse Academy™: Exploring an Advent of Targeted Therapies Across Advanced NSCLC Care and Strategies for Managing Adverse Events Associated With Treatment
Patient, Provider, and Caregiver Connection™: Shedding a Light on the Patient Journey with KRAS Mutated Lung Cancer
Clinical Vignettes®: Multidisciplinary Discussions on the Application of Novel EGFR Exon 20 Targeted Regimens for NSCLC Management
Expert Illustrations & Commentaries™: Exploring the Role of Novel Antibody-Drug Conjugates in Advanced NSCLC
Advances In™ NSCLC: Exploring CEACAM5 As A New Therapeutic Target
Community Practice Connections™: Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
Advances In™: The Role of NRG1 Fusions Across Tumor Types
Medical Crossfire®: Leveraging EGFR Mutation Profiles to Personalize Therapeutic Decisions in Resected and Metastatic NSCLC Settings
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Top 10 Oncogenic Markers in NSCLC for 2022: Evolution of Tumor Testing Technologies, Novel Treatments, and Trials!
Trevor M. Feinstein, MD, Reviews QOL Analysis of DUBLIN-3 Trial Comparing Docetaxel With or Without Plinabulin in NSCLCAugust 22nd 2022
Trevor M. Feinstein, MD, spoke about how quality of life was improved for patients with EGFR wild-type stage IIIB/IV non–small cell lung cancer receiving plinabulin in addition to docetaxel the phase 3 DUBLIN-3 trial.
Trevor M. Feinstein, MD, Examines Docetaxel With or Without Plinabulin in Stage IIIB/IV EGFR Wild-Type NSCLCAugust 22nd 2022
Trevor M. Feinstein, MD, discussed the phase 3 DUBLIN-3 trial evaluating docetaxel with or without plinabulin for patients with EGFR wild-type stage IIIB/IV non–small cell lung cancer.
Adjuvant Canakinumab Misses DFS End Point in R0 Resected Stage II-IIIA NSCLCAugust 21st 2022
In an update to the phase 3 CANOPY-A trial, investigators reported that canakinumab did not significantly improve disease-free survival over placebo in patients with completely resected non–small cell lung cancer.
Impressive Responses Observed With Ociperlimab Plus Tislelizumab in Treatment-Naïve, PD-L1+ NSCLCAugust 14th 2022
Ociperlimab plus tislelizumab showed promising antitumor activity in patients with treatment-naïve, metastatic, PD-L1–positive non–small cell lung cancer who were treated on the phase 1 AdvanTig-105 trial.
Tislelizumab Maintains OS Benefit vs Docetaxel in Previously Treated NSCLCAugust 13th 2022
Results from the phase 3 RATIONALE-303 trial presented at 2022 WCLC showed an overall survival benefit when patients with non–small cell lung cancer were treated with second- or third-line tislelizumab compared with docetaxel.
Roy S. Herbst, MD, PhD, Examines the Use of Ramucirumab Plus Pembrolizumab in ICI-Resistant Advanced NSCLCAugust 12th 2022
At ASCO 2022, Roy S. Herbst, MD, PhD, reviews a substudy of the phase 2 Lung-MAP trial which investigates ramucirumab plus pembrolizumab for patients with advanced non–small cell lung cancer who demonstrated resistance to previous immunotherapy.
Updated Results of VISION Trial Cohort C Reveal Positive Efficacy of Tepotinib in METex14-Altered NSCLCAugust 11th 2022
Results from cohort C of the phase 2 VISION trial showed continued efficacy when tepotinib was given to patients with non–small cell lung cancer harboring MET exon 14 skipping alterations.
Efficacy, Safety With Datopotamab Deruxtecan Plus Pembrolizumab Regimen Observed in Advanced NSCLCAugust 9th 2022
TROPION-Lung02 trial provides evidence of datopotamab deruxtecan and pembrolizumab efficacy in patients with advanced/metastatic non–small cell lung cancer and no actionable genomic alterations.
Brandon Sheffield, MD, Details NGS Benefits Vs Single-Gene Testing in NSCLCAugust 9th 2022
At the 2022 WCLC, Brandon Sheffield, MD, presented data demonstrating the advantage of next-generation sequencing over other biomarker testing strategies in patients with non–small cell lung cancer.
Frontline Tremelimumab/Durvalumab Combo Shows Promising Survival Benefit in Hard-to-Treat Subgroups of mNSCLCAugust 9th 2022
Patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations experienced a survival benefit following treatment with tremelimumab plus durvalumab and chemotherapy in the first line.
Half of Patients With Pretreated EGFR+ NSCLC Respond to Regimen Containing Amivantamab and LazertinibAugust 8th 2022
According to data from the phase 1 CHRYSALIS-2 trial that were presented at 2022 WCLC, a combination containing amivantamab, lazertinib, and chemotherapy was effective in patients with pretreated non–small cell lung cancer harboring EGFR mutations.
Addition of Tremelimumab to Durvalumab Regimen Induces Greater Survival Outcomes in PD-L1–Negative NSCLCAugust 8th 2022
The phase 3 POSEIDON trial showed superior overall survival in patients with PD-L1–negative metastatic non–small cell lung cancer who were given durvalumab and chemotherapy plus tremelimumab.
Neoadjuvant Nivolumab/Chemo Demonstrates Superiority Vs Chemo Alone in Resectable Stage IIIA/B NSCLCAugust 8th 2022
Data from the phase 2 NADIM II trial appear to reinforce the superiority of nivolumab and chemotherapy vs chemotherapy alone after the regimen significantly improved overall survival progression-free survival, and pathologic complete response in patients with stage IIIA/B non–small cell lung cancer, according to investigators.
CodeBreak100/101 Data Show Promise of Safety Lead-in With Sotorasib Plus Pembrolizumab for KRAS G12C+ NSCLCAugust 7th 2022
Following data presented from the phase 1/2 CodeBreak 100 and CodeBreak 101 trials, a regimen consisting of sotorasib with a safety lead-in followed by concurrent pembrolizumab will be further explored in patients with KRAS G12C–mutant non–small cell lung cancer.
Phase 2 Study Results Suggest Similar Efficacy, Safety of Sintilimab Vs Pembrolizumab in Advanced NSCLCAugust 7th 2022
Patients with treatment-naïve metastatic non–small cell lung cancer who received either sintilimab or pembrolizumab monotherapy, or either agent combined with chemotherapy, experienced comparable outcomes.
Differences in pCR and non-pCR Responders Support Use of Neoadjuvant Chemoimmunotherapy in Stage IIIA NSCLCAugust 7th 2022
Findings from the phase 2 NADIM trial reinforced the rationale for using neoadjuvant chemoimmunotherapy to treat patients with stage IIIA resectable non–small cell lung cancer based on differences between pathologic complete responders and non–pathologic complete responders
Ongoing Trial in KRAS G12C+ NSCLC Testing Neoadjuvant Adagrasib Plus/Minus Nivolumab Shoots for pCR ImprovementAugust 6th 2022
The phase 2 Neo-KAN study aims to determine if improved pathologic complete response rates with adagrasib alone or combined with immunotherapy for the neoadjuvant treatment of KRAS G12C–mutated non–small cell lung cancer are possible.
Promising Antitumor Activity Observed Following Treatment With Eftilagimod Alpha Plus Pembrolizumab for ICI-Resistant Advanced NSCLCAugust 6th 2022
A challenging patient population with advanced non–small cell lung cancer and resistance to common immunotherapeutics appeared to derive promising benefit from treatment with eftilagimod alpha plus pembrolizumab.